Get the Stockscreener App
15.35
3.76%
-0.60
Aurinia Pharmaceuticals Inc stock is traded at $15.35, with a volume of 1.67M.
It is down -3.76% in the last 24 hours and down -3.52% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$15.95
Open:
$15.88
24h Volume:
1.67M
Relative Volume:
1.17
Market Cap:
$2.02B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
35.70
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
-5.54%
1M Performance:
-3.52%
6M Performance:
+104.94%
1Y Performance:
+75.03%
1-Day Range:
$15.01
$15.97
1-Week Range:
$15.01
$16.16
52-Week Range:
$6.55
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.35 | 2.10B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 3.6%Here's Why - MarketBeat
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03 - MSN
Aurinia downgraded at RBC on risk-reward setup - MSN
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Is a Favorite Amongst Institutional Investors Who Own 54% - 富途牛牛
Spoke.comAurinia Pharmaceuticals IncCommon Shares (Nasdaq:AUPH) Stock Quote - FinancialContent
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? - AOL.com
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? - sharewise.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292% - simplywall.st
Understanding the Setup: (AUPH) and Scalable Risk - Stock Traders Daily
How Aurinia Pharmaceuticals Inc. (IKAP) stock trades pre earningsDebt-to-Equity Ratio Analysis & Watch and Learn From Live Trades - bollywoodhelpline.com
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month HighHere's Why - MarketBeat
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD - Investing.com
Why Aurinia Pharmaceuticals Inc. (IKAP) stock gets analyst attentionWeekly Market Outlook & Stock Timing and Entry Methods - Улправда
Chart Watch: Will Aurinia Pharmaceuticals Inc. stock pay special dividendsWall Street Watch & Free Risk Controlled Daily Trade Plans - Улправда
Will Aurinia Pharmaceuticals Inc. stock outperform international peersWeekly Stock Recap & Weekly High Return Stock Opportunities - Bölüm Sonu Canavarı
Is Aurinia Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Sector Moves & Community Verified Watchlist Alerts - DonanımHaber
Is Aurinia Pharmaceuticals Inc. (IKAP) stock undervalued after correction2025 Buyback Activity & Smart Swing Trading Techniques - DonanımHaber
Will Aurinia Pharmaceuticals Inc. stock benefit from automationPortfolio Value Report & Proven Capital Preservation Methods - DonanımHaber
How Aurinia Pharmaceuticals Inc. stock responds to policy changesBreakout Watch & Safe Entry Zone Tips - Улправда
Why retail investors favor Aurinia Pharmaceuticals Inc. stockJuly 2025 Highlights & Low Risk Profit Maximizing Plans - Улправда
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Squarepoint Ops LLC - MarketBeat
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Yahoo Finance
Marex Group plc Buys Shares of 135,000 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum - Yahoo Finance
How (AUPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit - MSN
Armistice Capital LLC Sells 3,370,400 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Jump Financial LLC - MarketBeat
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? - Yahoo Finance
Arrowstreet Capital Limited Partnership Has $9.12 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Earnings Report: Can Aurinia Pharmaceuticals Inc stock deliver 10 annual returns2025 AllTime Highs & Long-Term Safe Investment Ideas - moha.gov.vn
State Board of Administration of Florida Retirement System Has $1.22 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Schroder Investment Management Group Has $4.64 Million Holdings in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? - sharewise.com
Will Aurinia Pharmaceuticals Inc. (IKAP) stock return to pre crash levelsWeekly Trade Report & Low Risk Entry Point Guides - Newser
Can Aurinia Pharmaceuticals Inc. stock weather global recessionWeekly Trade Review & Detailed Earnings Play Alerts - Newser
How Aurinia Pharmaceuticals Inc. (IKAP) stock valuation compares with sectorJuly 2025 Action & High Accuracy Trade Signal Alerts - Newser
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Down 5.2%Time to Sell? - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Lowered to Hold Rating by Leerink Partnrs - MarketBeat
Can Aurinia Pharmaceuticals Inc. stock surprise with earnings upsideStock Surge & Reliable Price Breakout Signals - Newser
Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade - marketscreener.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shareholders Have Earned a 51% CAGR Over the Last Three Years - 富途牛牛
Leerink Partners downgrades Aurinia Pharmaceuticals stock rating on growth concerns - Investing.com Canada
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15 - marketscreener.com
Will Aurinia Pharmaceuticals Inc. stock sustain high P E ratios2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Defamation Litigation Roundup: FDA, Lively, Alexander Bros. - Law360
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):